UNSPSC 51312606: Nemazoline

This classification denotes a histamine-1 receptor antagonist and alpha-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QUV3YCP28R. European Medicines Agency schedules Nemazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09190MIG. Nemazoline generally arises in the molecular formula C10H11CL2N3.

UNSPSC 51312606 Nemazoline, a Commodity code, does not accurately describe the products actually being procured under the opportunities tagged with this code. State and local governments soliciting under this code are purchasing naloxone (opioid antagonist medications), safe drug deactivation systems, generic pharmaceuticals, and over-the-counter products through health and human services agencies and cooperative purchasing alliances—none of which align with nemazoline, an anthelmintic compound used to treat parasitic infections. The mismatch suggests either a data-entry error in the UNSPSC tagging or a misalignment between the code's nominal scope and current procurement practice. Recent solicitations show a mix of issuing bodies: Seminole County, Florida (a single county health procurement), the Texas Health and Human Services Commission (a state agency), and the Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of Minnesota Department of Administration (a multi-state cooperative vehicle). The work being solicited spans naloxone distribution for community health initiatives, exploratory market research for direct-to-manufacturer pharmaceutical contracting, and volume purchasing of generic drugs and OTC products through authorized wholesalers.

Geographic activity centers on Florida, Texas, and Minnesota based on recent opportunities. Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, posted June 30, 2026 with a response deadline of July 26, 2023, targets quarterly deliveries with all shipping and delivery costs included in vendor pricing; the contract includes a two-year initial term with one-year renewal option. The Texas HHS Commission's RFI posted April 3, 2026 seeks vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program as a preliminary market-intelligence phase to inform future RFP development. MMCAP's RFP posted January 20, 2026 with a response deadline of March 26, 2026 solicits generic multi-source pharmaceuticals and OTC products for distribution across Minnesota, Oregon, and participating state and local facilities through three authorized wholesalers, with awards effective July 1, 2026. The code shows limited relevant recent activity; the mismatch between its nominal definition and actual procurement warrants clarification before pursuing opportunities under this classification.